|
|
Volumn 1088, Issue , 2014, Pages 125-145
|
|
Engineering peptide therapeutics using mimetibody™ technology
a a a a |
|
Author keywords
Blood glucose; cAMP; Cell proliferation; Erythropoietin; Glucagon like 1 peptide; Hemoglobin; MIMETIBODY ; Pharamocokinetics; Transient expression
|
|
Indexed keywords
CNTO 2628;
CNTO 528;
CNTO 530;
CNTO 736;
CYTOKINE RECEPTOR AGONIST;
ERYTHROPOIETIN;
GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST;
GLUCOSE;
MIMETIBODY;
OLIGONUCLEOTIDE;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
AREA UNDER THE CURVE;
ARTICLE;
BLOOD GLUCOSE METER;
CELL PROLIFERATION;
CELL STRAIN HEK293;
DRUG ACTIVITY;
DRUG HALF LIFE;
GENE CONSTRUCT;
GLUCOSE BLOOD LEVEL;
GLUCOSE TOLERANCE TEST;
HUMAN;
HUMAN CELL;
LIPID DIET;
MALE;
MAXIMUM PLASMA CONCENTRATION;
MOLECULAR SIZE;
MOUSE;
NONHUMAN;
PLASMID;
PRIORITY JOURNAL;
PROTEIN ENGINEERING;
PROTEIN PURIFICATION;
RAT;
TRANSIENT TRANSFECTION;
ANIMALS;
BLOTTING, WESTERN;
CELL PROLIFERATION;
CYCLIC AMP;
ELECTROPHORESIS, POLYACRYLAMIDE GEL;
ENZYME-LINKED IMMUNOSORBENT ASSAY;
GENETIC VECTORS;
GLUCOSE TOLERANCE TEST;
HEK293 CELLS;
HUMANS;
MICE;
MICE, INBRED C57BL;
PEPTIDES;
PLASMIDS;
PROTEIN ENGINEERING;
RATS;
RATS, SPRAGUE-DAWLEY;
TRANSFECTION;
|
|
EID: 84934434290
PISSN: 10643745
EISSN: None
Source Type: Book Series
DOI: 10.1007/978-1-62703-673-3_9 Document Type: Article |
|
Times cited : (4)
|
|
References (7)
|
